<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene G446V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.G446V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity. <br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Highly resistant to mAbs SARS2-01, SARS2-02, SARS2-32 and SARS2-35 of 10 antibodies tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Massive reduction in binding efficiency vs wild type for mAb REGN10933.<br/> (<a href="https://doi.org/10.1126/science.abf4830" class="lit_link">Rappazzo et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> No effective neutralization in 3 out of the 4 sera tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  the early serum timepoint shows significant resistance (~10x or more), but both abate by the late timepoint (~3m)  presumably through immune cell somatic mutation evolution.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.02.003" class="lit_link">Greaney et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Ablation of neutralization capability of 3 convalescent sera tested, 1 improvement.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape) (<a href="https://doi.org/10.1016/j.cell.2020.07.012" class="lit_link">Li et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Most effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody.<br/>Most but only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody (<a href="https://doi.org/10.1016/j.chom.2020.11.007" class="lit_link">Greaney et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This individual mutation found in the epitope from Sotrovimab causes a 1.5x reduction in neutralization efficacy using a VSV model on Vero E6 cells.<br/> (<a href="https://doi.org/10.1101/2021.03.09.434607v9" class="lit_link">Cathcart et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Cligavimab lost ~16x binding against this isolated mutation.<br/>Imdevimab lost ~16x binding against this isolated mutation (the only RBD variant to do so). (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
